Medivir
MVIR | ST
Overview
Corporate Details
- ISIN(s):
- SE0000325151 (+4 more)
- LEI:
- 549300VWDGUX0WMJ1T79
- Country:
- Sweden
- Address:
- Box 1086, 141 22 Huddinge
- Website:
- https://www.medivir.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-07 15:30 |
Post-Annual General Meeting Information
Resolutions at the Annual General Meeting in Medivir on 7 May 2025
|
English | 40.6 KB | |
| 2025-05-07 15:30 |
Post-Annual General Meeting Information
Beslut vid årsstämma i Medivir den 7 maj 2025
|
Swedish | 40.8 KB | |
| 2025-04-29 08:30 |
Quarterly Report
|
Swedish | 395.9 KB | |
| 2025-04-29 08:30 |
Interim Report
|
English | 337.0 KB | |
| 2025-02-25 11:24 |
Major Shareholding Notification
|
Swedish | 9.1 KB | |
| 2025-02-18 08:30 |
Annual Report
|
Swedish | 410.1 KB | |
| 2025-02-18 08:30 |
Earnings Release
|
English | 339.3 KB | |
| 2025-02-03 10:37 |
Major Shareholding Notification
|
Swedish | 9.1 KB | |
| 2025-02-01 11:01 |
Major Shareholding Notification
|
Swedish | 8.9 KB | |
| 2024-10-24 08:50 |
Capital/Financing Update
Medivir erhåller en lånefacilitet om 30 miljoner kronor
|
Swedish | 48.5 KB | |
| 2024-10-24 08:50 |
Capital/Financing Update
Medivir receives loan facility of SEK 30 million
|
English | 47.3 KB | |
| 2024-08-22 08:30 |
Interim Report
|
Swedish | 391.8 KB | |
| 2024-08-22 08:30 |
Interim Report
|
English | 335.4 KB | |
| 2024-06-28 10:45 |
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Medivir AB on 28 June 2024
|
English | 175.8 KB | |
| 2024-06-28 10:45 |
Declaration of Voting Results & Voting Rights Announcements
Antalet aktier och röster i Medivir AB per den 28 juni 2024
|
Swedish | 168.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-05-10 | Uli Hacksell | Other | Buy | 24,978 | 192,274.70 SEK |
| 2021-05-07 | Uli Hacksell | Other | Buy | 25,022 | 193,031.97 SEK |
| 2021-03-16 | Bengt Julander | Other | Other | 3,600,000 | 27,828,000.00 SEK |
| 2021-03-05 | Magnus Christensen | Other | Buy | 3,956 | 33,626.00 SEK |
| 2021-03-05 | Magnus Christensen | Other | Buy | 2,044 | 17,435.32 SEK |
| 2021-03-05 | Helena Levander | Other | Buy | 24,390 | 207,315.00 SEK |
| 2021-03-04 | Helena Levander | Other | Buy | 17,868 | 151,878.00 SEK |
| 2021-03-03 | Helena Levander | Other | Buy | 242 | 2,057.00 SEK |
| 2021-03-01 | Yilmaz Mahshid | Other | Buy | 25,000 | 217,250.00 SEK |
| 2021-02-19 | Bengt Julander | Other | Other | 223,606 | 1,565,242.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |